367 Results for "

human IgG1 monoclonal

" in MedChemExpress (MCE) Product Catalog:
Products (367)

367 Results for "human IgG1 monoclonal" in MCE Product Catalog:

57
57 Publications Verification
Cat. No.: HY-P9905
CAS No.: 205923-56-4
Synonyms: C225; IMC-C225
Research Areas:  

Cancer

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-P99001

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology Cancer

Human IgG1 kappa, Isotype Control is a human monoclonal antibody that is the isotype control of human IgG1 kappa antibody .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-P9908
CAS No.: 331731-18-1
Synonyms: Anti-human TNF-alpha, human Antibody; ABBV-3373 Antibody

Target:  

TNF Receptor Bacterial

Research Areas:  

Inflammation/Immunology Cancer

Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-P9915
CAS No.: 945721-28-8
Synonyms: Anti-human CD38, human Antibody; HuMax-CD38; JNJ-54767414

Target:  

CD38 ADC Antibodies

Research Areas:  

Inflammation/Immunology Cancer

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-P9915A
CAS No.: 945721-28-8
Synonyms: Anti-human CD38, human Antibody (PBS)

Target:  

ADC Antibodies CD38

Research Areas:  

Cancer

Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-108730
CAS No.: 1537032-82-8
Synonyms: Anti-human PD-L1, human Antibody; MSB 0010718C; MSB0010718C

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-108730A
CAS No.: 1537032-82-8
Purity:  96.02%

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P99340
CAS No.: 2423014-07-5
Synonyms: VIR 7831; GSK-4182136

Target:  

SARS-CoV

Research Areas:  

Infection Cancer

Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P9901
CAS No.: 477202-00-9
Synonyms: MDX-010; BMS-734016

Target:  

CTLA-4

Research Areas:  

Cancer

Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P9909
CAS No.: 815610-63-0
Synonyms: CNTO-1275; L04AC05; TT-20

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology Cancer

Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99423
CAS No.: 2516243-54-0
Synonyms: ADG 20

Target:  

SARS-CoV

Research Areas:  

Infection

Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99229
CAS No.: 2254118-43-7
Synonyms: XMT-1535; Upinitatug

Target:  

ADC Antibodies

Research Areas:  

Cancer

Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99646
CAS No.: 2418540-63-1
Synonyms: MEDI6570

Target:  

LOX-1

Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-164153
ADC Control Human IgG1-vcMMAE (DAR4, solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-164152A
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-164152

Research Areas:  

Cancer

ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9801
Synonyms: SARS-CoV-2 (2019-nCoV) Spike RBD Antibody

Target:  

SARS-CoV

Research Areas:  

Infection

Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99271
CAS No.: 1418628-81-5
Synonyms: Anti-human F3 Recombinant Antibody

Target:  

ADC Antibodies

Research Areas:  

Cancer

Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99014
CAS No.: 1864871-20-4
Synonyms: ARGX-110

Research Areas:  

Inflammation/Immunology Cancer

Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9966
CAS No.: 1353485-38-7
Synonyms: MGA271

Target:  

CD276/B7-H3

Research Areas:  

Cancer

Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
loading...
    loading...